NAMS Stock Analysis: NewAmsterdam Pharma | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 3.960m USD | 12M Return: 90.1% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 35.0M
Warnings
Tailwinds
No distinct edge detected
Seasonality 5.4 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
NewAmsterdam Pharma Company N.V. (NAMS) is a late-stage biopharmaceutical company headquartered in Naarden, the Netherlands, focused on therapies for cardiometabolic disease. The company listed on NASDAQ on November 23, 2022, and is classified within the biotechnology sub-industry of the health care sector.
Its lead candidate, Obicetrapib, is an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor in clinical trials as both a monotherapy and in combination with ezetimibe to lower LDL-C in patients with cardiovascular disease. The same molecule is also being tested in a Phase 2a trial for Alzheimers disease. Consistent with the clinical-stage biotechnology model, NewAmsterdam Pharma has no approved products on the market, pursuing a multi-indication strategy for a single asset and depending on trial readouts and regulatory outcomes for future revenue.
- Obicetrapib Phase 3 LDL-C data readout catalysts
- FDA approval and commercial launch timeline
- Cash burn and equity dilution risk pre-revenue
| Net Income: -212.7m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.19 > 0.02 and ΔFCF/TA -2.21 > 1.0 |
| NWC/Revenue: 2.62k% < 20% (prev 1.65k%; Δ 970.4% < -1%) |
| CFO/TA -0.19 > 3% & CFO -141.9m > Net Income -212.7m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 9.76 > 1.5 & < 3 |
| Outstanding Shares: last quarter (121.1m) vs 12m ago 4.29% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 2.91% > 50% (prev 5.76%; Δ -2.85% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBIT TTM and Interest Expense TTM) |
| A: 0.81 (Total Current Assets 658.0m - Total Current Liabilities 67.4m) / Total Assets 732.6m |
| B: -1.11 (Retained Earnings -810.8m / Total Assets 732.6m) |
| C: -0.27 (EBIT TTM -212.7m / Avg Total Assets 775.5m) |
| D: 9.87 (Book Value of Equity 665.2m / Total Liabilities 67.4m) |
| Altman-Z'' = 10.20 = AAA |
| DSRI: 3.0 (Receivables 8.22m/1.61m, Revenue 22.6m/47.1m) |
| GMI: 1.03 (GM 99.76% / 97.04%) |
| AQI: 165.1 (AQ_t 0.10 / AQ_t-1 0.00) |
| SGI: 0.48 (Revenue 22.6m / 47.1m) |
| TATA: -0.10 (NI -212.7m - CFO -141.9m) / TA 732.6m) |
| Beneish M = 95.58 (Cap -4..+1) = D |
As of July 08, 2026, the stock is trading at USD 36.99 with a total of 958,652 shares traded. Over the past week, the price has changed by +9.21%, over one month by +19.52%, over three months by +9.08% and over the past year by +90.08%.
Current recommended Stop Loss: 34.90 (which is 5.7% or 1.2 ATR below the current price).
NewAmsterdam Pharma has received a consensus analysts rating of 4.56. Therefore, it is recommended to buy NAMS.
- StrongBuy: 5
- Buy: 4
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 49.7 | 34.3% |
P/S = 180.4461
P/B = 6.1807
Revenue TTM = 22.6m USD
EBIT TTM = -212.7m USD
EBITDA TTM = -212.5m USD
Long Term Debt = unknown (0.0)
Short Term Debt = 23.0k USD (from shortTermDebt, last quarter)
Debt = 23.0k USD (from shortLongTermDebtTotal, last quarter) (leases 23.0k already included)
Net Debt = -636.1m USD (calculated: Debt 23.0k - CCE 636.1m)
Enterprise Value = 3.32b USD (3.96b + Debt 23.0k - CCE 636.1m)
Interest Coverage Ratio = unknown (Ebit TTM -212.7m / Interest Expense TTM 0.0)
EV/FCF = -23.37x (Enterprise Value 3.32b / FCF TTM -142.2m)
FCF Yield = -4.28% (FCF TTM -142.2m / Enterprise Value 3.32b)
FCF Margin = -630.1% (FCF TTM -142.2m / Revenue TTM 22.6m)
Net Margin = -942.8% (Net Income TTM -212.7m / Revenue TTM 22.6m)
Gross Margin = unknown ((Revenue TTM 22.6m - Cost of Revenue TTM 668k) / Revenue TTM)
Tobins Q-Ratio = 4.54 (Enterprise Value 3.32b / Total Assets 732.6m)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 23.0k)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -168.1m (EBIT -212.7m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 9.76 (Total Current Assets 658.0m / Total Current Liabilities 67.4m)
Debt / Equity = 0.00 (Debt 23.0k / totalStockholderEquity, last quarter 665.2m)
Debt / EBITDA = 2.99 (negative EBITDA) (Net Debt -636.1m / EBITDA -212.5m)
Debt / FCF = 4.47 (negative FCF - burning cash) (Net Debt -636.1m / FCF TTM -142.2m)
Total Stockholder Equity = 713.8m (last 4 quarters mean from totalStockholderEquity)
RoA = -27.43% (Net Income -212.7m / Total Assets 732.6m)
RoE = -29.80% (Net Income TTM -212.7m / Total Stockholder Equity 713.8m)
RoCE = -29.80% (EBIT -212.7m / Capital Employed (Equity 713.8m + L.T.Debt 0.0))
RoIC = -25.31% (negative operating profit) (NOPAT -168.1m / Invested Capital 664.1m)
WACC = 9.29% (E(3.96b)/V(3.96b) * Re(9.29%) + D(23.0k)/V(3.96b) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 9.29% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 82.22 | Cagr: 18.62%
[DCF] Fair Price = unknown (Cash Flow -142.2m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.48 | # QB: 0
Revenue Correlation: 46.24 | Revenue CAGR: 43.17% | SUE: 0.18 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.42 | Chg30d=-0.21% | Revisions=+25% | Analysts=12
EPS next Quarter (2026-09-30): EPS=-0.42 | Chg30d=+2.72% | Revisions=+25% | Analysts=12
EPS current Year (2026-12-31): EPS=-1.59 | Chg30d=-0.27% | Revisions=+36% | GrowthEPS=-9.2% | GrowthRev=+22.8%
EPS next Year (2027-12-31): EPS=-1.32 | Chg30d=+3.76% | Revisions=+42% | GrowthEPS=+15.3% | GrowthRev=+464.6%
[Analyst] Revisions Ratio: +42% (up=22, down=8)